9.39
-0.48 (-4.86%)
| Previous Close | 9.87 |
| Volume | 128,855 |
| Price / Sales | 4.38 |
| Price / Book | 4.37 |
| 52 Weeks Range |
| Profit Margin | -42.99% |
| Operating Margin (TTM) | -76,248.27% |
| Diluted EPS (TTM) | -2.87 |
| Quarterly Revenue Growth (YOY) | -99.80% |
| Total Debt/Equity (MRQ) | 60.30% |
| Current Ratio (MRQ) | 6.62 |
| Operating Cash Flow (TTM) | -58.52 M |
| Levered Free Cash Flow (TTM) | 6.86 M |
| Return on Assets (TTM) | -17.83% |
| Return on Equity (TTM) | -50.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Precision BioSciences, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Relative Valuation | NA |
| Financial Health | 1.4 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.29 |
Select this tab to load the latest available analysis.
|
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.94% |
| % Held by Institutions | 42.73% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |